MICHAEL XING

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi request reprint Progress in molecular-based management of differentiated thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet 381:1058-69. 2013
  2. pmc Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 309:1493-501. 2013
  3. pmc Molecular pathogenesis and mechanisms of thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    Nat Rev Cancer 13:184-99. 2013
  4. pmc Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification
    Jeffrey C Xing
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    PLoS ONE 7:e49192. 2012
  5. pmc Oxidative stress: a new risk factor for thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Endocr Relat Cancer 19:C7-11. 2012
  6. pmc The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells
    Ruixin Liu
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 97:E173-82. 2012
  7. ncbi request reprint Gene methylation in thyroid tumorigenesis
    Mingzhao Xing
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, USA
    Endocrinology 148:948-53. 2007
  8. ncbi request reprint BRAF T1796A transversion mutation in various thyroid neoplasms
    M Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Endocrinol Metab 89:1365-8. 2004
  9. ncbi request reprint BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Endocr Rev 28:742-62. 2007
  10. pmc Recent advances in molecular biology of thyroid cancer and their clinical implications
    Mingzhao Xing
    Department of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Otolaryngol Clin North Am 41:1135-46, ix. 2008

Research Grants

  1. Genetic and Epigenetic Alterations in Thyroid Tumors
    MICHAEL XING; Fiscal Year: 2007
  2. Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
    MICHAEL MINGZHAO XING; Fiscal Year: 2010
  3. Genetic & Epigenetic Events in Papillary Thyroid Cancer
    MICHAEL MINGZHAO XING; Fiscal Year: 2010

Collaborators

Detail Information

Publications47

  1. doi request reprint Progress in molecular-based management of differentiated thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet 381:1058-69. 2013
    ..These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine...
  2. pmc Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 309:1493-501. 2013
    ..BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established...
  3. pmc Molecular pathogenesis and mechanisms of thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    Nat Rev Cancer 13:184-99. 2013
    ....
  4. pmc Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification
    Jeffrey C Xing
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    PLoS ONE 7:e49192. 2012
    ..Thus, the present study uncovers an interesting phenomenon that rs17849071G/T is protective against FTC possibly through preventing PIK3CA amplifications...
  5. pmc Oxidative stress: a new risk factor for thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Endocr Relat Cancer 19:C7-11. 2012
    ..These interesting possibilities deserve further studies...
  6. pmc The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells
    Ruixin Liu
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 97:E173-82. 2012
    ....
  7. ncbi request reprint Gene methylation in thyroid tumorigenesis
    Mingzhao Xing
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, USA
    Endocrinology 148:948-53. 2007
    ..Future studies need to emphasize the mechanistic aspects of these two types of epigenetic alterations to uncover new molecular mechanisms in thyroid tumorigenesis and to provide novel therapeutic targets for thyroid cancer...
  8. ncbi request reprint BRAF T1796A transversion mutation in various thyroid neoplasms
    M Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Endocrinol Metab 89:1365-8. 2004
    ....
  9. ncbi request reprint BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Endocr Rev 28:742-62. 2007
    ..With these advances, it has become clearer that BRAF mutation will likely have significant impact on the clinical management of PTC...
  10. pmc Recent advances in molecular biology of thyroid cancer and their clinical implications
    Mingzhao Xing
    Department of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Otolaryngol Clin North Am 41:1135-46, ix. 2008
    ..These exciting advances provide unprecedented opportunities for the development of molecular-based novel diagnostic, prognostic, and therapeutic strategies for thyroid cancer...
  11. pmc BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Clin Oncol 27:2977-82. 2009
    ..This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC)...
  12. pmc Prognostic utility of BRAF mutation in papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, United States
    Mol Cell Endocrinol 321:86-93. 2010
    ..Use of this unique molecular marker, in conjunction with conventional clinicopathological risk factors, to assist the prognostication of PTC is likely to improve the efficiency of contemporary management of thyroid cancer...
  13. pmc Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer
    Mingzhao Xing
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Thyroid 20:697-706. 2010
    ..As the drivers of this process, many genetic alterations activating the PI3K/Akt pathway have been identified in thyroid cancer in recent years...
  14. ncbi request reprint BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 90:6373-9. 2005
    ..Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer...
  15. ncbi request reprint BRAF mutation in thyroid cancer
    M Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St Suite 333 Baltimore, MD 21287, USA
    Endocr Relat Cancer 12:245-62. 2005
    ..This newly discovered BRAF mutation may prove to have an important impact on thyroid cancer in the clinic...
  16. ncbi request reprint Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 89:2867-72. 2004
    ..Thus, we have demonstrated the usefulness of BRAF mutation detection on FNAB specimens that can help diagnose and identify those PTC patients who may need more aggressive surgical treatment and vigilant clinical monitoring...
  17. ncbi request reprint The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Endocrinol (Oxf) 63:263-6. 2005
    ..As the somatic T1799A BRAF mutation is highly prevalent in papillary thyroid cancer, the aim was to test whether this mutation was a susceptibility mutation for FNMTC...
  18. ncbi request reprint BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells
    Dingxie Liu
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Clin Endocrinol Metab 92:2264-71. 2007
    ..Although the BRAF V600E mutant can initiate the formation of papillary thyroid cancer (PTC), it is unclear whether it is required to maintain cell proliferation, transformation, and tumor growth of BRAF mutation-harboring PTC...
  19. ncbi request reprint Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations
    Dingxie Liu
    Division of Endocrinology and Metabolism Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 92:4686-95. 2007
    ..Targeting MAPK kinase (MEK) in the MAPK pathway is a potentially effective therapeutic strategy for thyroid cancer...
  20. pmc Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways
    Dingxie Liu
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
    Thyroid 18:853-64. 2008
    ..The objective of this study was to use a potent new-generation MEK inhibitor PD0325901 to further investigate the therapeutic potential of specifically targeting MEK in the MAP kinase pathway for thyroid cancer...
  21. ncbi request reprint Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer
    Shuiying Hu
    Department of Medicine, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Int J Cancer 119:2322-9. 2006
    ..These results suggest that aberrant methylation and hence silencing of TIMP3, SLC5A8, DAPK and RARbeta2, in association with BRAF mutation, may be an important step in PTC tumorigenesis and progression...
  22. doi request reprint Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer
    Haixia Guan
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer 113:247-55. 2008
    ..It remains to be investigated whether the aberrant methylation of DNA repair genes plays a pathogenic role in BRAF mutation-promoted tumorigenesis of papillary thyroid cancer (PTC)...
  23. ncbi request reprint Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 64:1664-8. 2004
    ....
  24. ncbi request reprint BRAF mutation in papillary thyroid carcinoma
    Yoram Cohen
    Division of Head and Neck Cancer Research, Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    J Natl Cancer Inst 95:625-7. 2003
    ..Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer...
  25. pmc Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin
    Dingxie Liu
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 69:7311-9. 2009
    ..This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies...
  26. ncbi request reprint Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 90:4688-93. 2005
    ..As in many other human cancers, overactivation of the phosphotidylinositol 3-kinase (PI3K)/Akt signaling pathway occurs frequently in thyroid cancer, but the mechanism is not completely clear...
  27. doi request reprint Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors
    Peng Hou
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer 113:2440-7. 2008
    ..Epigenetic silencing of the PTEN gene, a negative regulator of the PI3K/AKT pathway, also occurs in thyroid tumors, but its relationship with genetic alterations in this pathway is unclear...
  28. doi request reprint Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer
    Yangang Wang
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Endocr Relat Cancer 15:183-90. 2008
    ..The data suggest that the BRAF T1799A mutation is associated with aggressive pathological outcomes of PTC in which high platelet counts and increased PDGF production may play a role...
  29. ncbi request reprint Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant
    Dingxie Liu
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 13:1341-9. 2007
    ....
  30. pmc Somatic mutation and gain of copy number of PIK3CA in human breast cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Breast Cancer Res 7:R609-16. 2005
    ..Even though PIK3CA amplification and somatic mutation have been reported previously in various kinds of human cancers, the genetic change in PIK3CA in human breast cancer has not been clearly identified...
  31. ncbi request reprint High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors
    Yangang Wang
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Clin Endocrinol Metab 92:2387-90. 2007
    ..Genetic alterations in the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and their role in thyroid tumor pathogenesis in Chinese people remain undefined...
  32. ncbi request reprint Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244
    Douglas W Ball
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 553, Baltimore, Maryland 21231 1000, USA
    J Clin Endocrinol Metab 92:4712-8. 2007
    ..MAPK kinase (MEK), immediately downstream of BRAF, is a promising target for ras-raf-MEK-ERK pathway inhibition...
  33. doi request reprint Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer
    Haixia Guan
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 94:1612-7. 2009
    ..Epidemiological studies have indicated that high iodine intake might be a risk factor for papillary thyroid cancer (PTC), which commonly harbors the oncogenic T1799A BRAF mutation...
  34. ncbi request reprint Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer
    Shuiying Hu
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 91:98-104. 2006
    ..Serum DNA methylation markers may potentially be useful in diagnosing thyroid cancer and monitoring its recurrence...
  35. ncbi request reprint Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors
    Biju Joseph
    Division of Endocrinology and Metabolism, Department of Meidcine, The Johns Hopkins University School of Medicine, 813 Hunterian Street, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 92:4766-70. 2007
    ..It remains inconclusive whether mutations in thyroid hormone receptor (TR) genes naturally occur in thyroid cancer and whether these genes could be suppressors of this cancer...
  36. pmc Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways
    Peng Hou
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 95:820-8. 2010
    ..Further studies are warranted to test this therapeutic potential in restoring radioiodine avidity of thyroid cancer cells for effective ablation treatment...
  37. ncbi request reprint Mitochondrial DNA alterations in thyroid cancer
    Betty C Tong
    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Surg Oncol 82:170-3. 2003
    ..The objective of the present study was to examine a series of thyroid cancers for genetic alterations in this region...
  38. ncbi request reprint DeltaNp63alpha up-regulates the Hsp70 gene in human cancer
    Guojun Wu
    Department of Otolaryngology Head and Neck Surgery, Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205 2196, USA
    Cancer Res 65:758-66. 2005
    ..Our study provides strong evidence for the physiologic association between DeltaNp63alpha and hsp70 in human cancer, thus further supporting the oncogenic potential of DeltaNp63alpha...
  39. ncbi request reprint Tumor-specific changes in mtDNA content in human cancer
    Elizabeth Mambo
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Int J Cancer 116:920-4. 2005
    ..Our findings suggest that mtDNA content can be used as a molecular diagnostic tool to help identify genetic abnormalities in human tumors...
  40. ncbi request reprint High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes
    Vasily Vasko
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 90:5265-9. 2005
    ..The role of the T1799A BRAF mutation in lymph node metastasis of papillary thyroid cancer (PTC) is not clear...
  41. doi request reprint Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers
    Zhi Liu
    Division of Endocrinology and Metabolism, Department of Pathology, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 93:3106-16. 2008
    ....
  42. ncbi request reprint Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer
    Peng Hou
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 13:1161-70. 2007
    ..To investigate the overall occurrence and relationship of genetic alterations in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in thyroid tumors and explore the scope of this pathway as a therapeutic target for thyroid cancer...
  43. ncbi request reprint Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing
    Mingzhao Xing
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 63:2316-21. 2003
    ..We propose that methylation of TSHR may provide a novel diagnostic marker of malignancy and a basis for potential use of demethylating agents in conjunction with TSH-promoted radioiodine therapy for epithelial thyroid cancers...
  44. ncbi request reprint Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 63:2312-5. 2003
    ..SLC26A4 gene methylation in benign adenomas and the relatively well-differentiated WRO cell line suggest that this alteration is an early event in thyroid tumorigenesis...
  45. pmc Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer
    Avaniyapuram Kannan Murugan
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Biochem Biophys Res Commun 393:555-9. 2010
    ..Thus, functionally relevant IDH1 mutations can also occur in thyroid cancer, particularly ATC, suggesting a potential tumorigenic role of the IDH1 system that could represent a new therapeutic target for thyroid cancer...
  46. pmc The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway
    Ruixin Liu
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 96:E577-85. 2011
    ..The phosphoinositide 3-kinase (PI3K)/Akt pathway is widely postulated to be an effective therapeutic target in thyroid cancer...
  47. pmc Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications
    Peng Hou
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    PLoS ONE 4:e6200. 2009
    ....

Research Grants7

  1. Genetic and Epigenetic Alterations in Thyroid Tumors
    MICHAEL XING; Fiscal Year: 2007
    ..We expect to discover important molecular information on the mechanisms of PTC pathogenesis and novel therapeutic targets for this most common endocrine cancer. ..
  2. Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
    MICHAEL MINGZHAO XING; Fiscal Year: 2010
    ....
  3. Genetic & Epigenetic Events in Papillary Thyroid Cancer
    MICHAEL MINGZHAO XING; Fiscal Year: 2010
    ..We expect to discover important molecular information on the mechanisms of PTC pathogenesis and novel therapeutic targets for this most common endocrine cancer. ..